lobbying_filings_raw: e862fd39-e23b-4401-afdd-3f9dc3fc55b3

Raw lobbying disclosure filings from the Senate Office of Public Records (SOPR). Each row is a single filing — registrations, quarterly reports, amendments, and terminations. Includes registrant and client names, reported income/expenses, filing period, and the full raw JSON from the API.

This data as json

filing_uuid filing_type registrant_id registrant_name client_id client_name filing_year filing_period received_date amount_reported is_amendment is_no_activity is_termination raw_json
e862fd39-e23b-4401-afdd-3f9dc3fc55b3 Q3 51478 TCH GROUP, LLC 157374 SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC ) 2013 third_quarter 2013-10-17T16:19:25.810000-04:00 40000.0 0 0 0 {"url": "https://lda.senate.gov/api/v1/filings/e862fd39-e23b-4401-afdd-3f9dc3fc55b3/", "filing_uuid": "e862fd39-e23b-4401-afdd-3f9dc3fc55b3", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2013, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/e862fd39-e23b-4401-afdd-3f9dc3fc55b3/print/", "filing_document_content_type": "text/html", "income": "40000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Mr. John Brad Holsclaw, Partner", "dt_posted": "2013-10-17T16:19:25.810000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "601 13th Street, NW, Suite 630 North", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20005", "registrant": {"id": 51478, "url": "https://lda.senate.gov/api/v1/registrants/51478/", "house_registrant_id": 34927, "name": "TCH GROUP, LLC", "description": "Government relations consulting firm", "address_1": "4937 Tilden St NW", "address_2": null, "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20016", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "MICHAEL A. TONGOUR", "contact_telephone": "+1 202-321-3579", "dt_updated": "2026-02-25T13:00:57.520798-05:00"}, "client": {"id": 157374, "url": "https://lda.senate.gov/api/v1/clients/157374/", "client_id": 75, "name": "SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )", "general_description": null, "client_government_entity": false, "client_self_select": null, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": null, "ppb_state_display": null, "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2007-08-03"}, "lobbying_activities": [{"general_issue_code": "TAX", "general_issue_code_display": "Taxation/Internal Revenue Code", "description": "Extension of the U.S. R&D tax credit; extending and maintaining the orphan drug tax credit", "foreign_entity_issues": "Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.", "lobbyists": [{"lobbyist": {"id": 5039, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "HOLSCLAW", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; FDA funding; NIH funding; general issues related to diabetes awareness; H.R.2094 and S.1503; issues related to the Independent Payment Advisory Board; general issues related to School Access to Emergency Epinephrine Act", "foreign_entity_issues": "Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation will benefit.", "lobbyists": [{"lobbyist": {"id": 5039, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "HOLSCLAW", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.", "foreign_entity_issues": "Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.", "lobbyists": [{"lobbyist": {"id": 5039, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "HOLSCLAW", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "ECN", "general_issue_code_display": "Economics/Economic Development", "description": "All provisions of HR 2052 and S 1023 \"Global Investment in American Jobs Act of 2013\"", "foreign_entity_issues": "Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.", "lobbyists": [{"lobbyist": {"id": 5039, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "HOLSCLAW", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "ANI", "general_issue_code_display": "Animals", "description": "Education and awareness of issues related to the compunding of medications for animal health, including all provisions of S 959 \"Pharmaceutical Compounding Quality and Accountability Act\"; all provisions of HR 1407 \"Animal Drug User Fee Amendments of 2013\" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 \"Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013\"", "foreign_entity_issues": "Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.", "lobbyists": [{"lobbyist": {"id": 5039, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "HOLSCLAW", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []}

Links from other tables